---
title: 'Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A:
  results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials'
date: '2024-12-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39642902/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241207173203&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Allogeneic haematopoietic stem-cell transplantation is the
  standard treatment for bone marrow failure (BMF) in patients with Fanconi anaemia,
  but transplantation-associated complications such as an increased incidence of subsequent
  cancer are frequent. The aim of this study was to evaluate the safety and efficacy
  of the infusion of autologous gene-corrected haematopoietic stem cells as an alternative
  therapy for these ...'
disable_comments: true
---
BACKGROUND: Allogeneic haematopoietic stem-cell transplantation is the standard treatment for bone marrow failure (BMF) in patients with Fanconi anaemia, but transplantation-associated complications such as an increased incidence of subsequent cancer are frequent. The aim of this study was to evaluate the safety and efficacy of the infusion of autologous gene-corrected haematopoietic stem cells as an alternative therapy for these ...